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Forget about shortcuts. Instead, enjoy the wonders of your path.  
Paolo Coello 
 
The coronary circulation is unique in its ability to autoregulate to metabolic demand. 
The ratio of maximal to resting blood flow was first called the coronary flow reserve 
(CFR) by Lance Gould in 1974.1 The practical challenges measuring CFR invasively 
add time and complexity to routine physiological lesion assessment. On the other 
hand, invasively measured CFR provides additional prognostic information in the 
40% of patients who have discordance between fractional flow reserve (FFR) and 
CFR. This discrepancy occurs because of fundamental differences in coronary 
pathophysiology in focal CAD and diffuse CAD.2 For example, an older diabetic 
patient with a diffusely diseased vessel, microvascular dysfunction but only minor 
focal stenosis may have a preserved FFR but impaired CFR (Figure 1). Both indices 
provide complementary information. Even amongst patients with preserved FFR 
(>0.8), abnormal CFR denotes those at higher risk of adverse events.3 Determination 
of CFR using only pressure measurements (FFR & Pd/Pa) is thus an attractive 
concept. 
1. Predicting CFR using the change between resting and 
hyperaemic pressure gradients 
Early correlation studies systematically underestimated true CFR by neglecting the 
important contribution of frictional forces to pressure drop.4 More recently the 
concept of “pressure-bounded CFR” (pb-CFR) was introduced. pbCFR uses Gould’s 
pressure-velocity relationships5  for a coronary stenosis to compute minimum and 
maximal values of CFR (Figure 1C – pressure gradient-velocity relationship). In 
essence, pb-CFR is a confidence interval of true CFR values. It examines the change 
between resting gradient (Pd/Pa or iFR) and hyperaemic lesion gradients (FFR). If 
the bounds (confidence intervals) of pb-CFR are under 2 it is categorised as reduced. 
Previous work has shown that low pb-CFR is associated with cardiac death and 
myocardial infarction (1.5% v 3%, adjusted HR 3.8;  95% CI 1.04-13.7). However, 
when revascularisation was included in a composite end-point, low pb-CFR was not 
predictive of major adverse cardiac events.6 Unfortunately, not all patients can be 
categorised as normal or abnormal. Around 40% of patients have ‘indeterminate pb-
CFR’ where the bounds cross the threshold of significance. 
2. What is the prognostic significance of indeterminate pb-CFR? 
Lee et al present a succinct article addressing the significance of ‘grey zone’ 
pb-CFR values by investigating outcomes according to the true (thermodilution-
derived) CFR in a cohort with indeterminate pbCFR. They provide useful insights 
into the topical area of FFR/CFR discordance in their study with median follow up 
approaching 4 years. 
This skilled group of coronary physiology researchers used their multicenter 
Korean registry to retrospectively analyse whether thermodilution-derived CFR 
(thermo-CFR) was predictive of events in 170 patients (179 lesions) with 
indeterminate pb-CFR. The vast majority of patients had stable angina with 
preserved FFR (>0.8) and at least one coronary artery with intermediate stenosis. 
The primary end-point was patient-oriented composite outcomes (POCO - a 
composite of all-cause mortality, myocardial infarction, and ischemia-driven 
revascularization). Roughly a quarter of the indeterminate pb-CFR group had a 
measured thermo-CFR that was abnormally reduced (<2). Known associates of 
reduced CFR were observed – the low thermo-CFR group were significantly older 
with functionally and anatomically more severe disease (lower FFR, higher SYNTAX 
& Gensini scores and lower minimum lumen diameter on angiography). They had a 
non-significant trend towards more diabetes and higher microvascular resistance. 
Unsurprisingly, the unadjusted risk of POCO was increased in this group. Notably, 
all-cause mortality was also far greater in this low thermo-CFR group (13.9% v 1.5%, 
95% CI 1.5-18.5, p=0.011). Even after adjustment for age, FFR and diabetes, there 
was still a striking increase in events amongst those with low thermo-CFR (aHR 9.8, 
95% CI 3.0-32.5, p<0.001). The authors themselves acknowledge the limitations of 
this modestly sized retrospective unblinded study. This may introduce bias as the 
physicians may have been aware of CFR and pb-CFR influencing the decision to 
revascularise driving POCO. Another limitation of pb-CFR relates to assessment of 
lesions with small gradients at rest. The ratio of pb-CFR is likely to be inaccurate 
where the resting gradient is less than 5mmHg because of larger relative error from 
typical pressure wire imprecision (+/- 2mmHg). 
3. What can we learn from this study by Lee et al?  
There are two important highlights. First, the authors have shown that 
attempting to estimate CFR using pressure only measurements (pb-CFR) will miss 
around a quarter of patients with truly low CFR. This figure is greater than the 
validation study where the indeterminate pb-CFR group was excluded (sensitivity of 
95.5% without the indeterminate group).7 It seems there is no easy shortcut when 
measuring CFR invasively. Second, this work supports the evolving literature 
regarding the incremental prognostic value of CFR even amongst patients without 
functionally significant epicardial stenosis. Full physiological assessment with both 
indices provides insights into the complex mechanisms of ischaemia in the individual 
patient. 
4. CFR/FFR discordance gives insight into what causes the 
patient’s ischemia  
 There is a clear relationship between high risk clinical variables (e.g. diabetes 
and advancing age) with a reduced CFR. Lesions with significant resting gradients 
(Pd/Pa, iFR® and diastolic resting indices) often have downstream compensatory 
microvascular dilation that maintains resting coronary flow at the expense of a 
reduced CFR.8 pb-CFR will highlight the clinician to some patients in this group. But 
what should we do with this information? These patients may have a worse prognosis 
and potentially more angina, but the pathophysiology in this group is varied and not 
specific to the focal epicardial lesion. Indeed, coronary physiology pioneers Lance 
Gould and Nils Johnson coined the phrase “physiological stenosis severity” which 
considers the in vivo transmural myocardial pressure gradient.9 As clinicians, we 
need to think outside the model of fixed epicardial physiology to consider the myriad 
of other contributors to reduced CFR and ischaemia. Factors including the 
vasomotor lesion ‘tone’, ventricular hypertrophy and myocardial compression, 
subendocardial viability ratio (Buckberg index), microvascular dysfunction, 
endothelial impairment and others.10 The pathophysiology in patients with reduced 
CFR is varied, but the natural history of these high risk patients with angina, diffuse 
atheroma and reduced CFR may be best improved with CABG.11 FFR may not be a 
panacea, but its strong correlation with relative coronary flow reserve12 lends 
methodological support for it to remain the gold standard. It identifies the relative 
significance of a focal stenosis that is more amenable to PCI than diffuse disease.  
5. Future perspectives: stratified trials to direct treatment 
A stratified approach to coronary artery disease would personalise 
revascularisation decisions based on physiological patterns and mechanisms of 
coronary disease. The goal being to maximally reduce symptoms, morbidity and 
mortality. Proving this hypothesis will require large randomised controlled trials 
using the patient (clinical events) as the gold standard. We need to think beyond 
fixed epicardial assessment. Appraising the change in translesion gradient between 
rest and hyperaemia, pb-CFR allows a better understanding of the pathophysiology 
(in some patients) although lacks accuracy to direct therapy. Ongoing studies that 
may provide insights into the utility of pressure and flow measurements in symptom 
relief and prognosis include the Ischemia trial, physiology outputs from the ORBITA 
trial as well as the DEFINE-FLOW (NCT02328820) study.  
Revascularisation decisions are only one part of treatment - there is a pressing 
need for improved medical treatments targeting diffuse and microvascular coronary 
disease. Like many things in life, there are no shortcuts here. Lee et al’s study on pb-
CFR reminds us that appreciating the underlying processes and the journey are key. 
  
Figure Legend –  
pb-CFR calculation worked example from pressure wire assessment of a 68-year-old 
female diabetic with angina and no obstructive coronary disease (ANOCA).  
A – Coronary angiography showing mild tandem stenoses in the left anterior 
descending artery.  
B – Notable resting translesion gradient (∆P=14mmHg) with only minimal further 
pressure drop at hyperaemia (∆P=18mmHg), symptoms of full adenosine effect were 
noted by the patient.  
C – Change in flow (CFR) plotted against change in translesional gradient based on 
Gould’s pressure gradient-velocity curves5 (∆P=f Q + s Q2). Q represents flow, f  is 
frictional losses whilst s represents separation losses before and after the stenosis. If 
all the pressure drop across a lesion relates to friction (mild/no stenosis) then the 
CFR will be higher and is calculated as hyperaemic ∆P divided by the resting ∆P. 
This is the upper bound of the CFR – in this case 1.3. The minimum possible CFR 
occurs where all the pressure drop relates to flow separation losses (severe stenosis) 
thus the lower bound of CFR is the square root of the figure above (√1.3) ≃ 1.2.  
D – pb-CFR in this worked example is categorised as reduced (<2) because the 
bounds (intervals) are under this threshold. In this case the actual measured CFR (by 
thermodilution) was 1.6 and the pb-CFR correctly predicted the reduced CFR. The 
microvascular resistance was elevated (IMR 36) and was an important contributor to 
the reduced CFR. This lady was randomised to full disclosure of coronary physiology 
results to help her physician stratify her treatment in the BHF CorMicA study 
(NCT03193294). The angina responded to stratified medical therapy including beta-
blockers, calcium channel blockers, aspirin and a statin. 
  
 Figure 1 
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